Literature DB >> 12558658

The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans.

M C Mackey1, A A G Aprikyan, D C Dale.   

Abstract

Using data on the fraction of post-mitotic neutrophil precursors (CD15+ cells) displaying positive markers for apoptosis in 12 normal humans, and a simple mathematical model, we have estimated the apoptotic rate to be about 0.28/day in this compartment. This implies that the influx of myelocytes into the post-mitotic compartment exceeds twice the granulocyte turnover rate (GTR), and that about 55% of the cells entering this compartment die before being released into the blood. The normal half life of apoptotic post-mitotic neutrophil precursors is calculated to be 10.4 h. Comparable calculations for patients indicate apoptosis rates in the post-mitotic compartment of about 17 times normal for one myelokathexis patient and rates of about 13 times normal for the one cyclical neutropenic patient and two severe congenital neutropenic patients. The estimated half life for apoptotic post-mitotic neutrophil precursors in the myelokathexis patient was about 0.4 h, 1.4 h in the cyclical neutropenia patient, and about 0.6 h in the severe congenital neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558658      PMCID: PMC6734917          DOI: 10.1046/j.1365-2184.2003.00251.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  28 in total

1.  Hematopoietic dynamics in grey collies.

Authors:  C Haurie; R Person; D C Dale; M C Mackey
Journal:  Exp Hematol       Date:  1999-07       Impact factor: 3.084

2.  Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis.

Authors:  J M Mahaffy; J Bélair; M C Mackey
Journal:  J Theor Biol       Date:  1998-01-21       Impact factor: 2.691

3.  Age-structured and two-delay models for erythropoiesis.

Authors:  J Bélair; M C Mackey; J M Mahaffy
Journal:  Math Biosci       Date:  1995 Jul-Aug       Impact factor: 2.144

4.  Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic, and cyclical neutropenic patients before and during treatment with G-CSF.

Authors:  C Haurie; D C Dale; M C Mackey
Journal:  Exp Hematol       Date:  1999-03       Impact factor: 3.084

5.  Neutrophil kinetics in man.

Authors:  J T Dancey; K A Deubelbeiss; L A Harker; C A Finch
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

6.  Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma.

Authors:  R S Anthony; N D McKelvie; A J Cunningham; J I Craig; S Y Rogers; A C Parker
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

7.  Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors.

Authors:  A A Aprikyan; W C Liles; J R Park; M Jonas; E Y Chi; D C Dale
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

Review 8.  Myeloid cell kinetics in response to haemopoietic growth factors.

Authors:  B I Lord
Journal:  Baillieres Clin Haematol       Date:  1992-07

9.  Haemopoietic cell kinetics in humans treated with rGM-CSF.

Authors:  B I Lord; H Gurney; J Chang; N Thatcher; D Crowther; T M Dexter
Journal:  Int J Cancer       Date:  1992-01-02       Impact factor: 7.396

10.  Cyclical neutropenia and the peripheral control of white blood cell production.

Authors:  T Hearn; C Haurie; M C Mackey
Journal:  J Theor Biol       Date:  1998-05-21       Impact factor: 2.691

View more
  12 in total

Review 1.  Phagocytic activity in human immunodeficiency virus type 1 infection.

Authors:  Agostino Pugliese; Valerio Vidotto; Tiziana Beltramo; Donato Torre
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

2.  Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

Authors:  M Scholz; C Engel; M Loeffler
Journal:  J Math Biol       Date:  2004-12-20       Impact factor: 2.259

3.  Aberrant subcellular targeting of the G185R neutrophil elastase mutant associated with severe congenital neutropenia induces premature apoptosis of differentiating promyelocytes.

Authors:  Pam Massullo; Lawrence J Druhan; Bruce A Bunnell; Melissa G Hunter; John M Robinson; Clay B Marsh; Belinda R Avalos
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

Review 4.  Congenital neutropenia: diagnosis, molecular bases and patient management.

Authors:  Jean Donadieu; Odile Fenneteau; Blandine Beaupain; Nizar Mahlaoui; Christine Bellanné Chantelot
Journal:  Orphanet J Rare Dis       Date:  2011-05-19       Impact factor: 4.123

Review 5.  Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?

Authors:  Alejandro A Schäffer; Christoph Klein
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-12

6.  Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Authors:  M Scholz; C Engel; D Apt; S L Sankar; E Goldstein; M Loeffler
Journal:  Cell Prolif       Date:  2009-09-24       Impact factor: 6.831

7.  Filgrastim improves survival in lethally irradiated nonhuman primates.

Authors:  Ann M Farese; Melanie V Cohen; Barry P Katz; Cassandra P Smith; Allison Gibbs; Daniel M Cohen; Thomas J MacVittie
Journal:  Radiat Res       Date:  2012-12-04       Impact factor: 2.841

8.  A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.

Authors:  M Scholz; M Ackermann; C Engel; F Emmrich; M Loeffler; M Kamprad
Journal:  Cell Prolif       Date:  2009-08-17       Impact factor: 6.831

9.  Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Authors:  O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

10.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.